YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Development of Vancomycin Dosing Nomogram Based on Clinical Pharmacokinetic Data of Korean Adult Patients

한국성인환자의 임상약동학 자료를 이용한 반코마이신 용량설정표 (nomogram)의 개발

  • 배성미 (가톨릭대학교 강남성모병원 약제과) ;
  • 김상일 (가톨릭대학교 강남성모병원 내과) ;
  • 강문원 (가톨릭대학교 강남성모병원 내과) ;
  • 조혜경 (이화여자대학교 약학대학)
  • Published : 2001.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

This research developed an intravenous (IV) vancomycin dosing nomogram based on the clinical pharmacokinetic data of Korean adult patients. Total 99 pairs of steady-state peak and trough serum concentrations of vancomycin were obtained from 73 adult patients in a tertiary general hospital. Serum vancomycin concentrations were determined to assess the appropriateness of initial vancomycin dosing. Only 47.2% of the cases were within therapeutic range. To characterize the clinical pharmacokinetics (PK) of vancomycin, PK parameters including elimination rate constant ( $K_{e}$) half-life( $T_{1}$2/), clearance (C $l_{van}$), volume of distribution ( $V_{d}$) were calculated by using one-compartment, first order pharmacokinetic equations. PK parameters were evaluated based on the differences of patients'renal function and age. Regression analysis showed a significant correlation between C $l_{van}$ and $C_{cr}$ (C $l_{van}$ = -1.89+0.914 $C_{cr}$ , r=0.763) and between $K_{e}$ and $C_{cr}$ , ( $K_{e}$=-0.0037+0.00139 $C_{cr}$ =0.724). The relationship between $K_{e}$ and $C_{cr}$ , and the mean $V_{d}$ were utilized for developing the nomogram to individualize the initial dosing regimen of vancomycin for the patients with various degrees of renal functions. The nomogram may be used as an efficient tool to determine safe and effective doses of vancomycin for the Korean adult patients.nts.nts.nts.s.nts.

Keywords

References

  1. J. Antimicrob. Chemother v.11 Vancomycin therapy of oxacillin-resistant Staphylococcus aureus infections Klastersky, J.;Coppens, L.;P van Auwera and Meunier-Carpentier, F.
  2. Rev. Infect. Dis. v.3 The Antibacterial action of vancomycin Watanakunakorn, C.
  3. J. Am. Chem. Soc. v.105 Vacomycin structure and transformation Harris, C.M.;Kopecka, H.
  4. 강남성모병원 원내 항균제 지침(1999) 강남성모병원
  5. JAMA v.269 The epidemiology of intravenous vancomycin usage in a university hospital;A 10-year study Ena, J.;Dick, R.W.;Jones, R.N.;Wenzel, R.P.
  6. J. Antimicrob Chemother. v.15 Vancomycin toxicity;A prospective study Meller, J.A.;Kingdom, J.;Cafferkey, M.
  7. Arch Intern. Med. v.149 Mild nephrotoxicity associated with vancomycin use Downs, N.J.;Neihart, R.E.;Dolezal, J.M.
  8. Antimicrob Agents Chemother v.23 Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981 Farber, B.F.;Moellering, R.C.
  9. Antimicrob. Agents Chemother v.36 Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharnacodynamic response Ackerman, B.H.;Vannier, A.M.;Eudy, E.B.
  10. Ther Drug Monit. v.20 Pharmacodynamics, pharmacokietics, and therapeutic drug monitoring of glycopeptides MacGowan, A.P.
  11. Antimicrob Agents Chemother v.35 Therapeutic monitoring of antimicrobials;a summary of the information presented at the UKNFQAS for antibiotic assays meeting for participants Reeves, D.S.;MacGowan, A.P.;Holt, H.A.;Lovering, A.M.;Warnock, D.W.;White, L.O.
  12. Antimicrob Agents Chemother v.34 Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection Peetermans, W.E.;Hoogeterp, J.J.;Hazekamp-Van Dokkum, A.M.
  13. Ann. Intern. Med. v.94 Vancomycin therapy in patients with impaired renal function;a nomogram for dosage Moellering, R.C.;Krogstad, D.J.;Greenblatt, D.F.
  14. Antimicrob. Agents Chemother v.25 Pharmacokinetics of vancomycin in patients with various degrees of renal function Matzke, G.R.;McGory, R.W.;Halstenson, C.E.;Keane, W.F.
  15. Antimicrob Agents Chemother v.32 Vancomycin Pharmacokinetics in patients with various degrees of renal function Rodvold, K.A.
  16. Am. J. Kidney Dis. v.11 Vancomycin dosing chart for use in patients with renal impairment Brown, D.L.;Mauro, L.S.
  17. Pharmacotherapy v.5 A simplified dosing method for initiating vancomycin therapy Lake, K.D.;Petersom, C.D.
  18. Ther Drug Monit. v.16 Vancomycin pharmacokinetics in a patients population;effect of age, gender, and body weight Ducharme, M.P.;Slaughter, R.L.;Edwards, D.J.
  19. Ther Drug Monit. v.12 Using Clinical data to determine vancomycin dosing parameters Birt, J.K.;Chandler, M.H.H.
  20. Nephron v.16 Prediction of creatinine clearance from serum creatinine Cockroft, D.W.;Gault, M.H.
  21. Clin. Pharmacokinet. v.9 Drug therapy in patients undergoing hemodialysis clinical pharmacokinetic considerations Lee, C.C.;Marbury, T.C.
  22. Clin. Pharm. v.10 Ethnicity and psychotropic drugs Bond, W.S.
  23. Clin. Pharmacokinet. v.7 Ethnic differences in drug metabolism Kalow, W.
  24. Clin. Pharmacokinet. v.20 Ethnic differences in drug disposition and responsiveness Wood, A.;Zhou, H.
  25. Clin. Pharmacol. Ther. v.36 Vancomycin disposition;the importance of age Cutler, N.R.;Narang, P.K.;Lesko, L.J.;Ninos, M.;Power, M.